Risk factors for mild cognitive impairment in Parkinson disease: a systematic review and meta-analysis
Yaodan Zhang1, Fang Chen2, Fengchun Ren3
1Department of Neurology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Background:
Mild cognitive impairment (MCI) is a common non-motor manifestation of Parkinson's disease (PD) and often precedes dementia. However, evidence on its demographic and clinical risk factors remains inconsistent. This study aimed to synthesize available data through a meta-analysis to identify determinants of MCI in PD.
Methodology:
This systematic review and meta-analysis followed PRISMA guidelines. Electronic databases were searched using MeSH terms and validated keywords. Studies were selected through a multi-step screening process by independent reviewers. Data extraction and quality assessment were performed using the Newcastle-Ottawa Scale. Meta-analyses were conducted using Comprehensive Meta-Analysis (v2). Random- or fixed-effects models were applied based on heterogeneity (I2 threshold = 50%). Beggs and Mazumdar test assessed publication bias, with significance set at (P < 0.1).
Results:
This meta-analysis included 33 studies, Significant risk factors for MCI in individuals with PD included older age (effect size = 0.4, 95% CI: 0.315-0.498, P ≤ 0.001), older age at disease onset (effect size = 0.18, 95% CI: 0.05-0.327, P ≤ 0.001), and longer disease duration (effect size = 0.14, 95% CI: 0.08-0.2, P ≤ 0.001). Higher educational attainment showed a protective effect (effect size = -0.438, 95% CI: -0.555 to -0.321, P ≤ 0.001). No significant association was found between gender and MCI (OR = 0.899, 95% CI: 0.749-1.079, P = 0.253). Disease severity, based on UPDRS and Hoehn and Yahr scales, was significantly associated with increased MCI risk.
Conclusion:
Advanced age, later disease onset, longer disease duration, and greater severity are key risk factors for MCI in PD. These findings highlight the need for early detection and proactive management to guide clinical decisions.
Insights
Mild cognitive impairment (MCI) in Parkinson's disease (PD) is linked to older age, later onset, and longer duration. Higher education offers protection, while disease severity increases risk.
Area of Science:
- Neurology
- Neuroscience
- Geriatrics
Background:
- Mild cognitive impairment (MCI) is a prevalent non-motor symptom in Parkinson's disease (PD), often preceding dementia.
- Risk factors for MCI in PD are not consistently established, necessitating comprehensive analysis.
Purpose of the Study:
- To conduct a systematic review and meta-analysis to identify demographic and clinical risk factors for MCI in Parkinson's disease.
- To synthesize existing data to provide a clearer understanding of MCI determinants in PD patients.
Main Methods:
- Systematic review and meta-analysis adhering to PRISMA guidelines.
- Searched electronic databases using MeSH terms and keywords, with multi-step screening by independent reviewers.
- Data extraction and quality assessment using the Newcastle-Ottawa Scale; meta-analyses performed using Comprehensive Meta-Analysis (v2).
Main Results:
- Older age, later age at PD onset, and longer disease duration were significant risk factors for MCI.
- Higher educational attainment demonstrated a protective effect against MCI in PD.
- Increased disease severity (UPDRS, Hoehn and Yahr scales) was significantly associated with higher MCI risk; gender was not a significant factor.
Conclusions:
- Advanced age, later disease onset, longer disease duration, and greater PD severity are key determinants of MCI.
- Findings underscore the importance of early detection and proactive management strategies for MCI in Parkinson's disease.
- Identifying these risk factors can aid in guiding clinical decisions and interventions for PD patients.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Neural Regulation
Pharmacodynamics in Geriatric Patients: Effects of Age
Dementia
The progression of dementia is generally gradual....


